Breadcrumb

Breadcrumbs

Press Releases

Press Releases

News, Events, Updates, Breakthroughs

Journalists may direct questions to mediainquiries@dsi.com. Or click here for direct contact information for Daiichi Sankyo U.S. Public Affairs team

Press announcements are archived by release date, searchable by topic:

From To
Date Title
Fri Jun 01 00:00:00 GMT-04:00 2018
Daiichi Sankyo Presents Long-Term Phase 1 Results of Antibody Drug Conjugate DS-8201 in Patients wi ...
PDF (203 KB)
Tue May 08 00:00:00 GMT-04:00 2018
Daiichi Sankyo Announces Single Agent Quizartinib Significantly Prolongs Overall Survival Compared ...
PDF (268 KB)
Mon Nov 20 00:00:00 GMT-04:00 2017
Daiichi Sankyo Initiates Pivotal Phase 2 Study of DS-8201 in Patients with HER2-Positive Advanced G ...
PDF (183 KB)
Wed Apr 04 00:00:00 GMT-04:00 2018
Daiichi Sankyo and DarwinHealth Enter Exclusive Research Collaboration for Novel Cancer Target Init ...
PDF (201 KB)
Tue Feb 06 00:00:00 GMT-04:00 2018
Daiichi Sankyo Initiates Phase 1 Study of U3-1402 in Patients with Metastatic EGFR-Mutated Non-Smal ...
PDF (180 KB)
Thu Feb 22 00:00:00 GMT-04:00 2018
Daiichi Sankyo Initiates Phase 1 Study of DS-1062 in Patients with Advanced Non-Small Cell Lung Can ...
PDF (181 KB)
Tue Dec 12 00:00:00 GMT-04:00 2017
Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in H ...
PDF (215 KB)
Thu Jan 18 00:00:00 GMT-04:00 2018
Daiichi Sankyo Presents Updated Data for DS-8201 in Patients with HER2-Expressing Gastric Cancer at ...
PDF (271 KB)
Thu Sep 14 00:00:00 GMT-04:00 2017
MD Anderson and Daiichi Sankyo Enter Research Collaboration to Accelerate Development of Acute Myel ...
PDF (260 KB)
Thu May 31 00:00:00 GMT-04:00 2018
Daiichi Sankyo Initiates Phase 2 Study of DS-8201 in Patients with Advanced HER2-Overexpressing or ...
PDF (189 KB)
Showing 1 - 10 of 38 results.

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...